Camurus AB (OSTO:CAMX) Long-Term Debt: kr0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:CAMX Camurus AB OSTO:CAMX
82 GF Score
Price kr619.00
GF Value kr677.94
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Camurus AB Long-Term Debt?

Camurus AB OSTO:CAMX -1.51% 82 Long-Term Debt is kr0 Mil as of Jun. 2026. GuruFocus rates OSTO:CAMX with a GF Score™ of 82/100 and a GF Value™ of kr677.94 (Fairly Valued). The stock has 2 warning signs investors should review.

Camurus AB's Long-Term Debt for the quarter that ended in Jun. 2026 was kr0 Mil.

Camurus AB  (OSTO:CAMX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Camurus AB Long-Term Debt Related Terms

Camurus AB Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Camurus AB's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camurus AB Long-Term Debt Chart

Camurus AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Camurus AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:CAMX
82GF Score
Camurus AB OSTO:CAMX
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of kr0 Mil mean?
Camurus AB (OSTO:CAMX) has a Long-Term Debt of kr0 Mil as of Jun. 2026.
Is Camurus AB's Long-Term Debt too high?
Camurus AB's current Long-Term Debt is kr0 Mil. Overall, Camurus AB has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Long-Term Debt compare to VRTX and REGN?
Camurus AB's Long-Term Debt of kr0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Camurus AB's current Long-Term Debt is kr0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (OSTO:CAMX) is currently considered Fairly Valued. The stock's GF Value™ is kr677.94, compared to a current price of kr619.00 — trading 8.7% below its estimated fair value. The current Long-Term Debt is kr0 Mil. Camurus AB's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Camurus AB (OSTO:CAMX), the current Long-Term Debt is kr0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Camurus AB (OSTO:CAMX) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of kr619.00 is trading 8.7% below its estimated GF Value™ of kr677.94. GuruFocus considers Camurus AB to be Fairly Valued.

Key valuation signals for OSTO:CAMX:

  • Long-Term Debt: kr0 Mil
  • GF Value™: kr677.94 vs. price of kr619.00 (8.7% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the OSTO:CAMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
82GF Score

Get the complete analysis for OSTO:CAMX

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr619.00
Price
kr677.94
GF Value